Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + XELOX in Advanced Gastric Cancer
NCT06776770Phase 2Recruiting
- Sponsor
- Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2024
- Primary completion
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Dose-limiting toxicity at 48 months, Maximum tolerated dose at 48 months and 2 more. Started Aug 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06776770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06776770.